Clinical Trial Update: Effectiveness of XCell on Autolytic Debridement of Venous Ulcers [NA]

View source ↗

Summary

This clinical trial update notes the completion of a study assessing XCell for autolytic debridement in venous ulcers. The sponsor is Xylos Corporation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Ulcer

Drugs mentioned

• XCell

Snippet

Sponsor: Xylos Corporation | Conditions: Venous Ulcer | NA | Status: COMPLETED